Table 7.
Antibiotic | MIC (µg/mL) |
OM-MRSA Isolates, No. (%) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ST8 (n = 24) | ST45 (n = 7) | ST59 (n = 37) | ST239 (n = 28) | |||||||||
t008-IV (n = 18) |
non-t008-IV a (n = 6) |
t026-IV (n = 1) |
t1081-IV(V) b (n = 6) |
t437-IV (n = 15) |
t437-V (n = 12) |
t441-IV (n = 2) |
t441-V (n = 6) |
non-t437/non-t441 c (n = 2) |
t037-III (n = 25) |
non-t037-III d (n = 3) |
||
Ciprofloxacin | (MIC ≥ 4) | 16 (89%) | 4 (67%) | 1 (100%) | 6 (100 %) | 2 (13%) | 1 (8%) | 1 (50%) | 0 | 0 | 25 (100%) | 3 (100%) |
Fusidic acid | (MIC ≥ 1) | 5 (28%) | 0 | 0 | 2 (33%) | 1 (7%) | 2 (17%) | 0 | 2 (33%) | 1 (50%) | 6 (12%) | 3 (100%) |
Gentamicin | (MIC ≥ 16) | 2 (11%) | 1 (17%) | 0 | 2 (33%) | 9 (60%) | 5 (42%) | 0 | 4 (67%) | 0 | 22 (88%) | 3 (100%) |
Rifampicin | (MIC ≥ 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TMP-SMX | (MIC ≥ 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 (100%) | 3 (100%) |
Vancomycin | (MIC ≥ 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (17%) | 0 | 3 (12%) | 1 (33%) |
a non-t008-IV: t008-V (n = 2), t441-IV (n = 1), t574-IV (n = 1), and t967-IV (n = 2). b t1081-IV (V): t1081-IV (n = 1) and t1081-V (n = 5). c non-t437/non-t441: t3485-V (n = 1) and t8391-V (n = 1). d non-t037-III: t037-IV (n = 2) and t037-V (n = 1). Abbreviations: OM, osteomyelitis; MRSA, methicillin-resistant Staphylococcus aureus; MIC, minimum inhibitory concentration; ST, sequence type; TMP-SMX, trimethoprim-sulfamethoxazole.